Archives — December 2016 back to current month (7)
The last several months have been active ones for Viveve: The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third-quarter financial results beat expectations, and the Viveve system has received regulatory approvals in Brazil, U.A.E. and Lebanon and FDA 510(k) clearance in the U.S.
VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco.
3D Signatures, a Canadian company developing a platform of "disruptive" personalized prognostic tests for patients with 13 different cancers and Alzheimer's disease, has attracted the attention of several stock watchers with its most recent announcements.
Technical analyst Clive Maund charts movements in the cannabis sector after the Nov. 8 legalization votes and the appointment of anti-cannabis firebrand Jeff Sessions as U.S. Attorney General.
Gecko Research discusses the bull market for marijuana, the road to legalization in Canada and why Emblem Corp., which begins trading on the TSX.V on Dec. 12 under the symbol EMC, is their top pick.
Reliq Health Technologies is initiating a trial of its remote patient monitoring system with The Feldman Institute in Louisiana, the fourth program for the company's innovative technology.
Can Biotech's Trump Bump Last? (12/02/2016)
In the weeks since Donald Trump's presidential election victory, the stock markets have ridden a wave into positive—and in the case of the Dow, record-breaking—territory. The so-called Trump Bump also sent biotech indices, flaccid for much of the year, up as much as 15%. With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office.
|"DRRX confirmed that it expects to complete patient follow-up visits this quarter, and announce top-line results from the Phase 3 PERSIST study in 4Q17."|
|"We believe that VIVE is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017."|